



**Fig. S1. Increased OL differentiation after long-term overexpression of *Nkx2.2* during embryonic period.** (A) Schedule for Dox treatment. (B-E) Immunolabeling of anti-Olig2 (B-C), anti-MBP (D-E) after Dox exposure from E12.5 to E18.5. Many MBP+ cells, represented by white arrowheads, were found in the ventral spinal cord of DTG while only few in the control (D-E). (F) Quantification of Olig2+, Sox10+ or MBP+ cells per section in control and DTG mouse spinal cords (mean±s.e.m.,  $n=3$ ). \*\*\*:  $P<0.001$ . Scale bar: 50  $\mu$ m.




**Fig. S2. Impaired OL proliferation and migration after induction of *Nkx2.2* in early OPCs.** (A-D') Double immunostaining of spinal cord sections from Dox-treated embryos (E12.5-E15.5) with anti-Olig2 and anti-BrdU (A-B''), anti-phospho Caspase-3 and anti-HA (C-D'). (E) Percentage of Olig2/BrdU double positive cells in Olig2+ cell population (mean±s.e.m.,  $n=3$ ). \*\*\*:  $P<0.001$ . (F-F') The majority of Sox10+ OPCs in the DTG spinal cord were restricted to the ventral half. Scale bar: A-D', 50  $\mu\text{m}$ ; F-F', 100  $\mu\text{m}$ .




**Fig. S3. Increased *PDGFRα* expression after conditional knockout of *Nkx2.2* in OLs.** *In situ* hybridization of Olig2 (A-D') and PDGFRα (E-H') probes in spinal cords from CNP<sup>+/cre</sup>;Nkx2.2<sup>+/-</sup> and CNP<sup>+/cre</sup>;Nkx2.2<sup>fl/fl</sup> from P3 to P21. There was an increase in the number of PDGFRα<sup>+</sup> OPCs, but not the total number of Olig2<sup>+</sup> OLs.






**Fig. S4. Delayed expression of mature OL marker CC1 in *Nkx2.2* conditional knockout.** Anti-CC1 immunostaining of spinal cord sections from CNP<sup>+cre</sup>;Nkx2.2<sup>+fl</sup> and CNP<sup>+cre</sup>;Nkx2.2<sup>fl/fl</sup> at P3 (A-A'), P7 (B-B'), P13 (C-C') and P21 (D-D').



**Fig. S5. Decreased *PDGFRα* expression after overexpressing *Nkx2.2* in primary OPCs.** (A-B') Immunostaining of *PDGFRα* in control (A-A') and *Nkx2.2*-overexpression (B-B') OPCs after the infection of lentivirus encodes GFP or *Nkx2.2*-GFP respectively. GFP expression did not affect *PDGFRα* expression, indicated by arrowheads in control (A-A'); while *Nkx2.2*-overexpression significantly suppressed *PDGFRα* expression, showed by arrow in (B-B'). (C) Detection of reduced *PDGFRα* in *Nkx2.2*-overexpressing OPCs by Western blot. GAPDH was loaded as internal control. Scale bar: 50  $\mu$ m.



**Fig. S6. Enhanced differentiation in primary OPCs overexpressing Nkx2.2.** (A-B) Anti-MBP immunostaining of rat OPCs infected by control lentivirus (A) or lentivirus encoding Nkx2.2 (B). (C) Quantification of MBP+ cells in control and Nkx2.2-overexpression OPCs 6 days after lentivirus infection. \*\*:  $P < 0.01$ . Scale bar: 50  $\mu\text{m}$ .